Real-world data of immunotherapy in combination with chemotherapy in elderly patients with previously untreated advanced non-small-cell lung cancer: A multicenter retrospective study (NEJ057)

Real-world data of immunotherapy in combination with chemotherapy in elderly patients with previously untreated advanced non-small-cell lung cancer: A multicenter retrospective study (NEJ057) - NEJ057

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046700

Enrollment

1000

Registered

2022-02-01

Start date

2022-01-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small-cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Cytologically or histologically confirmed non-small cell lung cancer 2 Clinical stage IIIB, IIIC without indication of definitive thoracic radiotherapy, stage IV, postoperative or radiotherapy recurrent disease 3 Patients who started first-line systemic therapy between December 2018 and March 2021 4 Patients who were over 75 years old at the initiation of first-line systemic therapy

Exclusion criteria

Exclusion criteria: 1 Patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) rearrangement 2 Patients whose attending doctor consider as inappropriate for this study 3 Patients whose first-line systemic therapy was molecular-targeted therapy

Design outcomes

Primary

Measure	Time frame
Progression-free survival	—

Secondary

Measure	Time frame
Overall survival Time-to-treatment-failure Response rate Safety Regimens selected as initial treatment Prognostic factors	—

Countries

Japan

Contacts

Public ContactYoko Tsukita

Tohoku University Graduate School of Medicine Department of Respiratory Medicine

y-tsukita@rm.med.tohoku.ac.jp022-717-8539

Outcome results